News

Novartis has a second positive phase 3 trial in the bag for its targeted factor B inhibitor iptacopan,

Novartis builds case for iptacopan as oral rival to PNH injectables

https://pharmaphorum.com/news/novartis-builds-case-for-iptacopan-as-oral-rival-to-pnh-injectables/

News/ News/ News/ Oncology/ R&D

GSK trumpets Jemperli vs Keytruda data in first-line NSCLC

Phil Taylor GSK, immuno-oncology, Jemperli, Keytruda, Merck & Co, Non-small cell lung cancer, Oncology 0 Comment

GSK says its PD-1 inhibitor Jemperli compared favourably with Merck & Co’s Keytruda in a head-to-head trial in

GSK trumpets Jemperli vs Keytruda data in first-line NSCLC

https://pharmaphorum.com/news/gsk-trumpets-jemperli-vs-keytruda-data-in-first-line-nsclc/

Digital/ News/ News/ News/ R&D

Investigation launched into alleged animal welfare violations at Neuralink

Phil Taylor animal testing, digital, digital health, Elon Musk, Neuralink 0 Comment

Elon Musk’s brain computer interface (BCI) company Neuralink is being investigated by law enforcement authorities in the US

Investigation launched into alleged animal welfare violations at Neuralink

https://pharmaphorum.com/news/investigation-launched-into-alleged-animal-welfare-violations-at-neuralink/

News/ News/ News/ Oncology/ R&D

Little Summit Therapeutics spends big bucks to rebuild pipeline

Phil Taylor Akeso, bispecific antibody, immuno-oncology, licensing, Non-small cell lung cancer, Oncology, Summit Therapeutics 0 Comment

$500 million upfront and a total deal value of up to $5 billion sounds like a deal made

Little Summit Therapeutics spends big bucks to rebuild pipeline

https://pharmaphorum.com/news/little-summit-therapeutics-spends-big-bucks-to-rebuild-pipeline/

1200px-Human_Natural_Killer_Cell_(29120480442)

News/ News/ News/ Oncology/ R&D

New Nkarta data backs up natural killer approach to cancer treatment

Phil Taylor car-nk, immuno-oncology, natural killer cells, Nkarta, non-Hodgkin lymphoma, Oncology 0 Comment

Harnessing the power of natural killer (NK) cells to attack cancer is as-yet an unproven strategy in oncology

New Nkarta data backs up natural killer approach to cancer treatment

https://pharmaphorum.com/news/new-data-backs-up-nkarta-natural-killer-approach-to-cancer/

Dengue, zika and chikungunya fever mosquito (aedes aegypti) on human skin

News/ News/ R&D

Valneva eyes first place in chikungunya vaccine race

Phil Taylor Bharat Biotech, chikungunya, Emergent BioSolutions, infectious diseases, vaccine, Valneva 0 Comment

Valneva has moved a step closer to its goal of becoming the first company to file for approval

Valneva eyes first place in chikungunya vaccine race

https://pharmaphorum.com/news/valneva-eyes-first-place-in-chikungunya-vaccine-race/

Cancer/ News/ News/ News/ Oncology/ R&D

Novartis’ Pluvicto presents survival benefit for castration-resistant prostate cancer

Nicole Raleigh Novartis, Oncology, Pluvicto, Prostate cancer, PSMAfore study, radioligand therapy, VISION study 0 Comment

It has been announced today that Novartis’ Pluvicto (lutetium vipivotide tetraxetan) has shown statistically significant and clinically meaningful

Novartis’ Pluvicto presents survival benefit for castration-resistant prostate cancer

https://pharmaphorum.com/news/novartis-pluvicto-presents-survival-benefit-for-castration-resistant-prostate-cancer/

Market Access/ News/ News/ News/ News/ Oncology/ R&D

GSK cancer division delivers good news after string of R&D setbacks

Phil Taylor endometrial cancer, GlaxoSmithKline, immuno-oncology, Jemperli, momelotinib, myelofibrosis, Oncology 0 Comment

GSK has reported much-needed progress with two of its cancer therapies, with a phase 3 trial win for

GSK cancer division delivers good news after string of R&D setbacks

https://pharmaphorum.com/news/gsk-cancer-division-delivers-good-news-after-string-of-rd-setbacks/

News/ News/ R&D

Amgen to push latecomer obesity drug into midstage testing

Phil Taylor AMG 133, Amgen, Eli Lilly, metabolic diseases, Novo Nordisk, obesity, tirzepatide, Wegovy 0 Comment

Amgen is lagging behind rivals like Novo Nordisk and Eli Lilly with its new-generation therapy for obesity, but

Amgen to push latecomer obesity drug into midstage testing

https://pharmaphorum.com/news/amgen-to-push-latecomer-obesity-drug-into-midstage-testing/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

News

Login